@article{8da63ecfeb1644808e27ce6accd9a1fb,
title = "Migraine Progression: A Systematic Review. An Editorial Comment",
author = "Buse, \{Dawn C.\} and Greisman, \{Jacob D.\} and Khosrow Baigi and Lipton, \{Richard B.\}",
note = "Funding Information: Disclosures: Dawn C. Buse, PhD, in the past 12 months, has received grant support and honoraria from Allergan, Amgen, Avanir, Biohaven, Eli Lilly, Promeius, and Teva. She is on the editorial board of Current Pain and Headache Reports. Jacob D. Greisman, BA has nothing to disclose. Khosrow Baigi, MD, MPH has nothing to disclose. Richard B. Lipton, MD is the Edwin S. Lowe Professor of Neurology at the Albert Einstein College of Medicine in New York. He receives research support from the NIH: 2PO1 AG003949 (Program Director), 5U10 NS077308 (PI), 1RO1 AG042595 (Investigator), RO1 NS082432 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of Neurology and as senior advisor to Headache. He has reviewed for the NIA and NINDS, holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Colucid, Dr. Reddy{\textquoteright}s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKlein, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from Wolff{\textquoteright}s Headache, 8th Edition, Oxford Press University, 2009, Wiley and Informa.",
year = "2019",
month = jul,
day = "1",
doi = "10.1111/head.13573",
language = "English (US)",
volume = "59",
pages = "974--976",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "7",
}